Idiopathic retroperitoneal fibrosis: Less common cause of low back pain. Use of tamoxifen in the treatment of the diesease


Authors: P. Němec 1;  S. Rybníčková 2;  P. Fabian 3;  Z. Fojtík 4;  M. Souček 1
Authors‘ workplace: Revmatologická ambulance II. interní kliniky, Fakultní nemocnice u sv. Anny v Brně, Lékařská fakulta Masarykovy Univerzity, 2Oddělení radiologie Masarykův onkologický ústav, 3Oddělení patologie Masarykův onkologický ústav, 4Revmatologická ambulance Intern 1
Published in: Čes. Revmatol., 16, 2008, No. 1, p. 23-29.
Category: Case Report

Overview

Retroperitoneal fibrosis (RPF) is a rare inflammatory disease which is characterized by the development of a fibrous process that surrounds the major vessels and organs located within the retroperitoneum. About two-thirds of all cases of RPF are idiopathic and are thought to be immunological in origin. Diagnosis of RPF should be considered in patients with unexplained abdominal and low back pain and retroperitoneal lesions. We present a case report of 59-year-old white male with idiopathic RPF with history of low back pain and weight loss as only symptoms, treated by tamoxifen, corticosteroids, and by insertion of JJ endoureteric catheters due to the obstruction of the upper urinary tract.

Key words:
low back pain, retroperitoneal fibrosis, tamoxifen, treatment


Sources

1. Ormond J. Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process. J Urol 1948; 1072-9.

2. McDougal WS, MacDonell RC Jr. Treatment of idiopathic retroperitoneal fibrosis by immunosuppression. J Urol 1991; 145: 112–4.

3. Hoffman WW, Trippel OH. Retroperitoneal fibrosis: etiological considerations. J Urol 1961; 86: 222–31.

4. Amis ES Jr. Retroperitoneal fibrosis. AJR Am J Roentgenol 1991; 157: 321 – 9.

5. Mitchinson MJ. Chronic periaortitis and periarteritis. Histopathology 1984; 8: 589–600.

6. Parums DV. The spectrum of chronic periaortitis. Histopathology 1990; 16: 423–31.

7. Kinzbrunner B, Ritter S, Domingo J, Rosenthal CJ. Remission of rapidly growing desmoid tumors after tamoxifen therapy. Cancer 1983; 52: 2201–4.

8. Clark CP, Vanderpool D, Preskitt JT. The response of retroperitoneal fibrosis to tamoxifen. Surgery 1991; 109: 502–6.

9. Loffeld RJ, van Weel TF. Tamoxifen for retroperitoneal fibrosis. Lancet 1993; 341: 382.

10. Frankart L, Lorge F, Donckier J. Tamoxifen for retroperitoneal fibrosis. Postgrad Med J 1997; 73: 653–4.

11. Owens LV, Cance WG, Huth JF. Retroperitoneal fibrosis treated with tamoxifen. Am Surg 1995; 61: 842–4.

12. Bourouma R, Chevet D, Michel F, Cercueil JP, Arnould L, Rifle G. Treatment of idiopathic retroperitoneal fibrosis with tamoxifen. Nephrol Dial Transplant 1997; 12: 2407–10.

13. Ozener C, Kiris S, Lawrence R, Ilker Y, Akoglu E. Potential beneficial effect of tamoxifen in retroperitoneal fibrosis. Nephrol Dial Transplant 1997; 12: 2166–8.

14. Chambers JC, McGovern K. Tamoxifen for retroperitoneal fibrosis. Palliat Med 2005; 19: 163–4.

15. Ergun I, Keven K, Canbakan B, Ekmekci Y, Erbay B. Tamoxifen in the treatment of idiopathic retroperitoneal fibrosis. Int Urol Nephrol 2005; 37: 341–3.

16. van Bommel EF, Hendriksz TR, Huiskes AW, Zeegers AG. Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med 2006; 144: 101–6.

17. Vaglio A, Greco P, Buzio C. Tamoxifen therapy for retroperitoneal fibrosis. Ann Intern Med 2006; 144: 619. author reply 619–20.

18. Parums DV, Brown DL, Mitchinson MJ. Serum antibodies to oxidized low-density lipoprotein in chronic periaortitis. Arch Pathol Lab Med 1990; 114: 383–7.

19. Vaglio A, Corradi D, Manenti L, Ferretti S, Garini G, Buzio C. Evidence of autoimmunity in chronic periaortitis: a prospective study. Am J Med 2003; 114: 454–62.

20. Littlejohn JO, Keystone EC. The association of retroperitoneal fibrosis with systemic vasculitis and HLA-B27: a case report and review of literature. J Rheumatol 1981; 8: 665–9.

21. De La Iglesia Martinez F, Grana Gil J, Gomez Veiga F, et al. The association of retroperitoneal fibrosis and ankylosing spondylitis. J Rheumatol 1992; 19: 1147–9.

22. Ter Maaten JC, Franssen CFM, Daenekkindt AA, Hoorntje SJ. Triple Wegener‘s granulomatosis in the urogenital tract. Nephron 1993; 63: 358–9.

23. De Roux-Serratrice C, Serratrice J, Granel B, et al. Periaortitis heralding Wegener‘s granulomatosis. J Rheumatol 2002; 29: 392–4.

24. Hautekeete ML, Babany G, Marcellin P, et al. Retroperitoneal fibrosis after surgery for aortic aneurysm in a patient with periarteritis nodosa: successful treatment with corticosteroids. J Intern Med 1990; 228: 533–6.

25. Machado EBV, Michet CJ, Ballard D, et al. Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota,1950–1985. Arthritis Rheum 1988; 31: 745–9.

26. Rasmussen TE, Hallet JW Jr. Inflammatory aortic aneurysm—a clinical review with new perspectives in pathogenesis. Ann Surg 1997; 225: 155–64.

27. Nitecki SS, Hallett JW Jr, Stanson AW, et al. Inflammatory abdominal aortic aneurysm: new clinical implication from a case–control study. J Vasc Surg 1996; 23: 860–9.

28. Tanaka S, Komori K, Okadome K, et al. Detection of active cytomegalo virus infection in inflammatory aortic aneurysms with RNA polymerase chain reaction. J Vasc Surg 1994; 20: 235–43.

29. Rasmussen TE, Hallett JW Jr, Metzger RLM, et al. Genetic risk factors in inflammatory abdominal aortic aneurysms: polymorphic residue 70 in the HLA-DRB1 gene as a key genetic element. J Vasc Surg 1997; 25: 356–64.

30. Martorana D, Vaglio A, Greco P. et al. Chronic periaortitis and HLA-DRB1*03: another clue to an autoimmune origin. Arthritis Rheum 2006; 55: 126-30.

31. R. N. Jois, K. Gaffney, T. Marshall and D. G. I. Scott Chronic periaortitis. Rheumatology 2004; 43: 1441–1446

32. Degesys GE, Dunnick NR, Silverman PM, Cohan RH, Illescas FF, Castagno A. Retroperitoneal fibrosis: use of CT in distinguishing among possible causes. AJR Am J Roentgenol 1986; 146: 57–60.

33. Glazer HS, Lee JK, Levitt RG et al. Radiation fibrosis: differentiation from recurrent tumor by MR imaging. Radiology 1985; 156: 721–6.

34. Yuh WT, Barloon TJ, Sickels WJ, Kramolowsky EV, Williams RD. Magnetic resonance imaging in the diagnosis and followup of idiopathic retroperitoneal fibrosis. J Urol 1989; 141: 602–5.

35. Dixon AK, Mitchinson MJ, Sherwood T. Computed tomographic observations in periaortitis. a hypothesis. Clin Radiol 1984; 35: 39–42.

36. Hricak H, Higgins CB, Williams RD. Nuclear magnetic resonance imaging in retroperitoneal fibrosis. AJR Am J Roentgenol 1983; 141: 35–8.

37. Artom A, Gandolfo N. Idiopathic retroperitoneal fibrosis: a case report without increased levels of acute-phase reactants. Noninvasive diagnosis and treatment Ann Ital Med Int 2004; 19: 50–3.

38. Kubota Y, Nomura Y, Tamaki M, Maeda S, Deguchi T. Four cases of idiopathic retroperitoneal fibrosis markedly responsive to steroid therapy. Hinyokika Kiyo 2005; 51: 315–9.

39. Kardar AH, Kattan S, Lindstedt E, Hanash K. Steroid therapy for idiopathic retroperitoneal fibrosis: dose and duration J Urol 2002; 168: 550–5.

40. Hollingworth P, Denman AM, Gumpel JM. Retroperitoneal fibrosis and polyarteritis nodosa successfully treated by intensive immunosuppression. J R Soc Med 1980; 73: 61–4.

41. Maillart E, Laueriere L, Kassis S, Moulonguet-Doleris L, Prinseau J, Baglin A, Hanslik T. Is there an evidence-based management of idiopathic retroperitoneal fibrosis? Rev Med Interne 2006; 27: 854–7.

42. Recloux P, Weiser M, Piccart M, Sculier JP. Ureteral obstruction in patients with breast cancer. Cancer 1988; 61: 1904–7.

43. Benson JR, Baum M. Tamoxifen for retroperitoneal fibrosis. Lancet 1993; 341: 836.

44. Vignon F, Bouton MM, Rochefort H. Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens. Biochem Biophys Res Commun 1987; 146: 1502–8.

45. Ramshaw AL, Parums DV. The distribution of adhesion molecules in chronic periaortitis. Histopathology 1994; 24: 23–32.

46. Horgan K, Cooke E, Hallett MB, Mansel RE. Inhibition of protein kinase C mediated signal transduction by tamoxifen. Importance for antitumour activity. Biochem Pharmacol 1986; 35: 4463–5.

47. Greengard P. Phosphorylated proteins as physiologic effectors. Science 1978; 199: 146–52.

Labels
Dermatology & STDs Paediatric rheumatology Rheumatology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account